Off-the-Shelf immune cells take on tough blood cancers

NCT ID NCT06552416

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new treatment called MT-401-OTS for people with relapsed acute myeloid leukemia or high-risk myelodysplastic syndromes. The therapy uses donor immune cells specially trained to attack cancer, and is given as a one-time infusion. The main goals are to check safety and find the right dose, while also seeing if it helps control the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MDS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • City of Hope Center (City of Hope National Medical Center, City of Hope Medical Center)

    RECRUITING

    Duarte, California, 91006, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • KU Cancer Center

    RECRUITING

    Kansas City, Kansas, 66160, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Moffitt Cancer Center

    RECRUITING

    Tampa, Florida, 33612, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••